Finn, R. S., et al. Treatment effect of palbociclib (PAL) plus endocrine therapy (ET) by prognostic and intrinsic subtype: A joint analysis of PALOMA2 and PALOMA3. Abstract presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2018 Jun 2; Chicago, IL.
Sinn, B. V., et al Targeted mRNA sequencing using small formalin-fixed, paraffin embedded core biopsies to evaluate immune and tumor-associated gene expression in breast cancer. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany, Abstract #AG13.03
Cascione L, et. al., Analysis of gene and protein expression in lymphoma cell lines using multiple platforms. Abstract #4275 presented at American Association of Cancer Research Annual Meeting; 2018 Apr 17, Chicago, IL.
Koshkin, V. S., et al. Prognostic value of CD56, ASCL1, and other biomarkers in small cell bladder cancer (SCBC). Poster session presented at: 2018 Genitourinary Cancers Symposium; 2018 Feb 9; San Francisco, CA. J Clin Oncol 36, 2018 (suppl 6S; abstr 452).
Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].
PMID: 29066507
Gaikwad, S. M., et al. Effective targeting of MYC expression with a novel nucleic acid binding (G4-quadruplex) small molecule coupled with HDAC inhibition synergizes to limit myeloma growth. Abstract presented at: American Association of Clinical Research (AACR) Annual meeting 2017; April 1-5, Washington, DC. DOI:10.1158/1538-7445.AM2017-194.
Schordan, E., et al. Rabiopred, an innovative theragnostic tool for precision medicine in rheumatoid arthritis patients. Abstract presented at Annual European congress of Rheumatology, 2017 JUN 14-17. Annals of the Rheumatic Diseases 2017 (76) S2:1463-1463. DOI: 10.1136/annrheumdis-2017-eular.6417
Aggen, D. H., et al. Biomarkers for immunotherapy in bladder cancer: a moving target. Journal for ImmunoTherapy of Cancer (2017) 5:94 DOI 10.1186/s40425-017-0299-1
Pierard, L., et al. Involvement of Angiogenin in Sunitinib Resistance in Human renal Cell Carcinoma. The Journal of Urology 2017; 197, No. 4S, Supplement e966.
Hamaldi, I., et al. LIM1 Oncogene as a New Therapeutic Target in Advanced Human Renal Cell Carcinoma, The Journal of Urology2017; 197, No. 4S, Supplement e793
Aggen, D. H., and Drake, C. G. Biomarkers for immunotherapy in bladder cancer: a moving target. Journal for ImmunoTherapy of Cancer (2017) 5:94
Sharma P., et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar 18(3):312
PMID: 28131785
Page last updated May 22, 2023